Key features and details
- Rabbit polyclonal to FGFR1 Oncogene Partner
- Suitable for: IHC-P, WB
- Reacts with: Human
- Isotype: IgG
Product nameAnti-FGFR1 Oncogene Partner antibody
See all FGFR1 Oncogene Partner primary antibodies
DescriptionRabbit polyclonal to FGFR1 Oncogene Partner
Tested applicationsSuitable for: IHC-P, WBmore details
Species reactivityReacts with: Human
Recombinant fragment within Human FGFR1OP-FGFR1 (internal sequence). The exact sequence is proprietary.
Database link: O95684
- WB: Raji whole cell lysate. IHC-P: Human lung cancer tissue.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7.00
Preservative: 0.01% Thimerosal (merthiolate)
Constituents: 1.21% Tris, 0.75% Glycine, 20% Glycerol (glycerin, glycerine)
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab229012 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC-P||1/100 - 1/1000.|
|WB||1/500 - 1/3000. Predicted molecular weight: 43 kDa.|
FunctionRequired for anchoring microtubules to the centrosomes.
Tissue specificityUbiquitous. Highly expressed in heart, liver, muscle, kidney, intestine, colon, adrenal gland, prostate, testis, and pancreas.
Involvement in diseaseNote=A chromosomal aberration involving FGFR1OP may be a cause of stem cell myeloproliferative disorder (MPD). Translocation t(6;8)(q27;p11) with FGFR1. MPD is characterized by myeloid hyperplasia, eosinophilia and T-cell or B-cell lymphoblastic lymphoma. In general it progresses to acute myeloid leukemia. The fusion proteins FGFR1OP-FGFR1 or FGFR1-FGFR1OP may exhibit constitutive kinase activity and be responsible for the transforming activity.
Sequence similaritiesBelongs to the FGFR1OP family.
Contains 1 LisH domain.
Cellular localizationCytoplasm > cytoskeleton > centrosome. Associated with gamma-tubulin.
- Information by UniProt
- FGFR1 oncogene partner antibody
- FGFR1OP antibody
- Fibroblast growth factor receptor 1 oncogene partner antibody
Anti-FGFR1 Oncogene Partner antibody (ab229012) at 1/1000 dilution + Raji (human Burkitt's lymphoma cell line) whole cell lysate at 30 µg
Predicted band size: 43 kDa
10% SDS-PAGE gel.
Paraffin-embedded human lung cancer tissue stained for FGFR1 Oncogene Partner using ab229012 at 1/500 dilution in immunohistochemical analysis.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab229012 has not yet been referenced specifically in any publications.